The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic (COVID-19)
The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic: A Descriptive Study of Patients With SARS-CoV-2 RT-PCR Performed
Hong Kong public healthcare system is facing tremendous pressure under the COVID-19 pandemic. As the virus spread in Hong Kong, Hong Kong Sanatorium & Hospital (HKSH) is one of the first private hospitals which immediately provide reliable and rapid COVID-19 test -- Reverse Transcription Polymerase Chain Reaction (RT-PCR). Early provision of the RT-PCR screening test for COVID-19 not only facilitates identification of COVID-19 but also contains the spread of the virus in the community and frontline medical staff.
Since description of role of private hospital in Hong Kong amid COVID-19 pandemic is lacking, this study will describe COVID-19 screening algorithm and methodology. A retrospective analysis on clinical characteristics, laboratory findings as well as outcome of patients who underwent COVID-19 test in HKSH is also performed.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Hong Kong, Hong Kong
- Hong Kong Sanatorium & Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects who underwent COVID-19 test in HKSH during the study period
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Subjects underwent COVID-19 test
Subjects who underwent COVID-19 test in HKSH during the study period
|
COVID 19 Diagnostic Test
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of asymptomatic subjects
Time Frame: 1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
|
Proportion of asymptomatic subjects (%) who underwent COVID 19 test
|
1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of subjects with recent contact history
Time Frame: 1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
|
Proportion of subjects (%) with recent contact history
|
1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
|
|
Proportion of subjects with recent travel history
Time Frame: 1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
|
Proportion of subjects (%) with recent travel history
|
1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jonpaul Sze Tsing Zee, MBChB, Hong Kong Sanatorium & Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RC-2020-08
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID
-
NCT06156176RecruitingFatigue | Post-COVID-19 Syndrome | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19 | Long-COVID | Post-COVID Condition
-
NCT07312357Not yet recruitingPost COVID Syndrome | Long Covid | Long COVID Fatigue | Post COVID Syndrome Long Covid
-
NCT06923137Active, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 Infection
-
NCT04434417Completed
-
NCT04467112Completed
-
NCT07013903RecruitingPost COVID Syndrome | Post-COVID / Long-COVID | POST-Covid 19 | Post-COVID Condition
-
NCT06267300Not yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID Condition
-
NCT05817032RecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19
-
NCT05198388Recruiting
-
NCT04346602Unknown
Clinical Trials on COVID 19 Diagnostic Test
-
NCT04525911Active, not recruiting
-
NCT04360811Completed
-
NCT07190131CompletedInfluenza A | COVID - 19 | Influenza B
-
NCT07308158CompletedInfluenza A | COVID - 19 | RSV | Influenza B
-
NCT04387968CompletedCoronavirus Infection
-
NCT04981769Not yet recruiting